Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that, in contrast to E-cadherin, mutations of alpha- and beta-catenin do not contribute to the pathogenesis or the diffuse growth patterns of gastric or breast carcinomas.
|
8548773 |
1996 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study indicated that the genetic polymorphisms of CDH1 and CTNNB1 were associated with breast cancer susceptibility and patients' prognosis.
|
26285011 |
2015 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we report a comprehensive study of the contribution of genetic variation in six genes encoding the beta-catenin destruction complex (APC, AXIN1, AXIN2, CSNK1D, CSNK1E, and GSK3B) to breast cancer using a Mayo Clinic Breast Cancer Case-Control Study.
|
18708403 |
2008 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For this reason, in present study, the alterations (deletion/methylation/mutation/expression) of MCC and CTNNBIP1 were analyzed in BC of Indian patients (N=120) followed by expression/mutation analysis of β-catenin.
|
27208794 |
2016 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations and deletions that result in the stabilization of beta-catenin are frequently found in a number of tumors, including those of the colon, the liver and the ovary, but are less frequently found in breast cancer.
|
12631383 |
2003 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Nuclear localization of β-catenin showed significant association with alterations in the antagonists and was also significantly high in the ER-/PR- BC samples.
|
22026417 |
2012 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Wnt signaling is associated with initiation and progression process in many tumor types, and alterations in β-Catenin explain only a small proportion of aberrant signaling found in breast cancer, indicating that other Wnt signaling components and/or regulators as GSK3β may be involved.
|
27983530 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.
|
20507565 |
2010 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We evaluated AXIN2 rs2240308 and rs151279728 polymorphisms, and expression profiles of β-catenin destruction complex genes in breast cancer patients.
|
26514524 |
2015 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Whereas some oncogenic pathways have high correlations to breast cancer subtype (RAS, CTNNB1, p53, HER1), others have high variability of activity within a specific subtype (MYC, E2F3, SRC), reflecting biology independent of common clinical factors.
|
19638211 |
2009 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry (IHC) was performed to assess the prevalence of MAGE-A, vimentin, E-cadherin and β-catenin in breast cancer tissues and correlate them with clinical pathological parameters.
|
26639233 |
2016 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
β-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells.
|
24401947 |
2014 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Beta-catenin and cyclin D1: connecting development to breast cancer.
|
14712077 |
2004 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although mutation of APC or CTNNB1 (beta-catenin) is rare in breast cancer, activation of Wnt signalling is nonetheless thought to play an important role in breast tumorigenesis, and epigenetic silencing of Wnt antagonist genes, including the secreted frizzled-related protein (SFRP) and Dickkopf (DKK) families, has been observed in various tumours.
|
18283316 |
2008 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggested that Mn12Ac inhibited the migration, invasion, and epithelial-mesenchymal transition by regulating Wnt/β-catenin and PI3K/AKT signaling pathways in breast cancer.
|
29316252 |
2018 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies.
|
12439718 |
2002 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells.
|
24897117 |
2014 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of DVL3 resulted in upregulation of β‑catenin and amplification of breast cancer cell growth, which confirmed that Wnt/β‑catenin activation via DVL3 is associated with breast cancer oncogenesis.
|
28035400 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Natural phytochemicals modulate oxidative stress, leptin, integrin, HER2, MAPK, ERK, Wnt/β-catenin and NFκB signaling along with regulating ERα and ERβ, thereby presenting unique opportunities for both primary and combinatorial interventions in BC.
|
28975625 |
2018 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results indicate that CUL1 knockdown prohibited the metastasis behaviors of breast cancer cells through downregulation (dephosphorylation) of the EMT signaling pathways of EGFR and Akt/GSK3β/β-catenin in breast cancer.
|
31175550 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
|
28103884 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
β-Catenin Mediates Anti-adipogenic and Anticancer Effects of Arctigenin in Preadipocytes and Breast Cancer Cells.
|
28279068 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings provide a new perspective to counteract the invasive behavior of breast cancer, indicating that blocking PI3K-AKT pathway-dependent β-catenin accumulation may represent a potential therapeutic approach to control breast cancer.
|
28522609 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data delineate a signaling pathway from ErbB2 to Pak to β-catenin that is required for efficient transformation of mammary epithelial cells, and suggest new therapeutic strategies in ErbB2-positive breast cancer.
|
23576562 |
2013 |